Analysis of glucagon-like peptide 1; what to measure?

Clinica Chimica Acta

Volumn 412, Issue 13-14, 2011, Pages 1191-1194

  Heijboer, Annemieke C ^a   Frans, Anneke ^a   Lomecky, Marie ^a   Blankenstein, Marinus A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Analysis; DPP4 inhibitor; Glucagon like peptide 1; Gut hormone; Immunoassay

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; MEASUREMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STANDARDIZATION;

CLINICAL CHEMISTRY TESTS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; POSTPRANDIAL PERIOD;

EID: 79955466457     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.010     Document Type: Article

References (18)

1. Vilsboll T., Holst J.J., Knop F.K. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Pract Res Clin Endocrinol Metab 2009, 23:453-462.
2. Hellstrom P.M. GLP-1: broadening the incretin concept to involve gut motility. Regul Pept 2009, 156:9-12.
3. Sulistio M., Carothers C., Mangat M., Lujan M., Oliveros R., Chilton R. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep 2009, 11:93-99.
4. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253-260.
5. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
6. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
7. Vilsboll T., Agerso H., Krarup T., Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
8. Meier J.J., Nauck M.A., Kranz D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53:654-662.
9. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42:658-661.
10. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
11. Knudsen L.B., Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318:429-435.
12. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004, 36:761-765.
13. Hupe-Sodmann K., McGregor G.P., Bridenbaugh R., et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995, 58:149-156.
14. Plamboeck A., Holst J.J., Carr R.D., Deacon C.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005, 48:1882-1890.
15. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
16. Vermeulen MA, Richir MC, Garretsen MK, et al. Gastric emptying, glucose metabolism and gut hormones: Evaluation of a common preoperative carbohydrate beverage. Nutrition in press.
17. Passing H., Bablok A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983, 21:709-720.
18. Deacon C.F., Holst J.J. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 2009, 23:425-432.